CRUSIA

Crusia is a pharmaceutical company and a specialized subsidiary of Laboratorios Farmacéuticos Rovi (ROVI), primarily focused on the commercialization of enoxaparin sodium biosimilars. The company's lead product, marketed under the brand name Crusia, is a low molecular weight heparin (LMWH) used for the prevention and treatment of venous thromboembolic diseases. Crusia serves as a key commercial vehicle for ROVI's expansion into European markets, providing healthcare systems with high-quality, cost-effective anticoagulant options. The company leverages ROVI's vertically integrated manufacturing process, which ensures a consistent supply of heparin-derived products. Crusia's portfolio is centered on addressing critical needs in hematology and cardiology, specifically in the management of deep vein thrombosis and pulmonary embolism. The company operates as a dedicated entity to manage the distribution and market presence of ROVI's heparin portfolio across various international territories.